BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8767035)

  • 1. [Deficit schizophrenia: from pharmacology to clinical practice].
    Tassin JP
    Encephale; 1996 Jun; 22 Spec No 2():9-12. PubMed ID: 8767035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
    Winterer G
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S68-71. PubMed ID: 16508900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective.
    Tanaka S
    Neuroscience; 2006 Apr; 139(1):153-71. PubMed ID: 16324800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine, the prefrontal cortex and schizophrenia.
    Knable MB; Weinberger DR
    J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus on the use of substituted benzamides in psychiatric patients.
    Racagni G; Canonico PL; Ravizza L; Pani L; Amore M
    Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR; Chen L
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psychopharmacologic approaches to schizophrenic psychoses].
    Giacardy-Paty M; Soubrouillard C; Blin O
    Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
    Lidow MS; Elsworth JD; Goldman-Rakic PS
    J Pharmacol Exp Ther; 1997 Apr; 281(1):597-603. PubMed ID: 9103549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
    Semkovska M; Bédard MA; Stip E
    Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha1-adrenergic, D1, and D2 receptors interactions in the prefrontal cortex: implications for the modality of action of different types of neuroleptics.
    Gioanni Y; Thierry AM; Glowinski J; Tassin JP
    Synapse; 1998 Dec; 30(4):362-70. PubMed ID: 9826228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study.
    Gurevich EV; Joyce JN
    Biol Psychiatry; 1997 Oct; 42(7):529-45. PubMed ID: 9376449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological markers in schizophrenia].
    Lembreghts M; Ansseau M
    Encephale; 1993; 19(5):501-23. PubMed ID: 8306920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuropathology of schizophrenia.
    Bachus SE; Kleinman JE
    J Clin Psychiatry; 1996; 57 Suppl 11():72-83. PubMed ID: 8941174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
    Mouri A; Noda Y; Noda A; Nakamura T; Tokura T; Yura Y; Nitta A; Furukawa H; Nabeshima T
    Mol Pharmacol; 2007 Jun; 71(6):1598-609. PubMed ID: 17344353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of prefrontal cortex dopaminergic modulation during the delayed alternation task.
    Dreher JC; Guigon E; Burnod Y
    J Cogn Neurosci; 2002 Aug; 14(6):853-65. PubMed ID: 12191453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.
    Okubo Y; Suhara T; Suzuki K; Kobayashi K; Inoue O; Terasaki O; Someya Y; Sassa T; Sudo Y; Matsushima E; Iyo M; Tateno Y; Toru M
    Nature; 1997 Feb; 385(6617):634-6. PubMed ID: 9024661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
    Moxon KA; Gerhardt GA; Adler LE
    Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.